Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/manishvinayak.
Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/prandi_fr.
J Card Fail. 2024 Oct;30(10):1302-1318. doi: 10.1016/j.cardfail.2024.06.018.
Secondary mitral regurgitation (SMR) is associated with increased mortality and heart failure hospitalizations. The management of heart failure patients with SMR is complex and requires a multidisciplinary Heart Team approach. Guideline-directed medical therapies remain fundamental, yet in a proportion of patients SMR persists. In the past decade, transcatheter edge-to-edge repair (TEER) has been shown to improve survival in patients with SMR who remain symptomatic despite medical therapy. Technical advancements across newer generations of devices, improved imaging, and greater operator expertise have collectively contributed to the increased safety and efficacy of this procedure over time. Various emerging transcatheter mitral valve repair and replacement devices are currently under investigation and may offer superior, complementary or synergistic treatment options in patients ineligible for TEER. This review provides a state-of-the-art overview regarding the diagnosis of SMR, and currently available transcatheter mitral valve interventions and describes a contemporary approach to the management of SMR.
二尖瓣反流(MR)与死亡率和心力衰竭住院率增加有关。有 SMR 的心力衰竭患者的管理很复杂,需要多学科心脏团队的方法。指南指导的药物治疗仍然是基础,但在一部分患者中,MR 仍然存在。在过去十年中,经导管缘对缘修复(TEER)已被证明可改善尽管接受药物治疗但仍有症状的 SMR 患者的生存率。随着时间的推移,新技术设备的技术进步、改进的成像和更多的操作人员专业知识,共同提高了该手术的安全性和有效性。目前正在研究各种新兴的经导管二尖瓣修复和置换装置,它们可能为不适合 TEER 的患者提供更好、互补或协同的治疗选择。本文综述了 SMR 的诊断以及目前可用的经导管二尖瓣介入治疗,并描述了 SMR 的现代治疗方法。